Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

Introgen Therapeutic’s (Austin, TX) p53-based INGN 225 cancer vaccine yielded promising safety and efficacy results in a Phase II trial in advanced small cell lung cancer. The personalized therapeutic ...

CAMBRIDGE, Mass., June 04, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the rAAVrh74 viral vector ...

OCZ Technology tipped its hand on Vector 150 when we reviewed the Vertex 450 a few months ago. At the time we didn't speculate on it, but privately I figured this signaled OCZ's move to IMFT 20nm ...